NCT07439653招募中1 期
A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 155
- 试验地点
- 6
研究概览
简要总结
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
- •Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
- •At least 1 measurable lesion per Lugano criteria.
- •Tumor tissue is available.
- •Adequate organ function
排除标准
- •T-cell lymphoma
- •CLL or SL
- •Burkitt lymphoma and high-grade B-cell lymphoma
- •CNS involvement
- •Peripheral neuropathy > Grade 2
- •Uncontrolled medical conditions
- •Viral infections
研究者
研究点 (6)
Loading locations...
相似试验
招募中
1 期
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCCHead and Neck CancerNCT07462377EpiBiologics110
尚未招募
1 期
Study of TYK-01054 Capsules in Patients With Advanced Solid TumorsNCT07282873TYK Medicines, Inc219
招募中
2 期
SKB500 Combinations in Patients With Small Cell Lung CancerSmall Cell Lung CancerNCT07296809Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.80
招募中
1 期
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS MutationsColorectal NeoplasmsNon-Small Cell Lung CancerNCT07629960Blueprint Medicines Corporation265
招募中
1 期
Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal CancerNCT07462650Beijing Biotech48